- Home
- DGICB vs VNDA Comparison
DGICB vs VNDA Comparison
Compare DGICB & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | VNDA |
|---|---|---|
| Founded | 1986 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.0M | 474.0M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | DGICB | VNDA |
|---|---|---|
| Price | $16.07 | $6.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.63 |
| AVG Volume (30 Days) | 7.3K | ★ 1.0M |
| Earning Date | 02-19-2026 | 02-11-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | ★ 219.91 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $987,826,105.00 | $216,105,000.00 |
| Revenue This Year | $2.26 | $12.01 |
| Revenue Next Year | $2.96 | $24.28 |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | 0.89 | ★ 8.72 |
| 52 Week Low | $13.19 | $3.81 |
| 52 Week High | $20.46 | $9.60 |
Technical Indicators
Market Signals| Indicator | DGICB | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 36.57 |
| Support Level | $15.85 | $6.01 |
| Resistance Level | $19.69 | $7.65 |
| Average True Range (ATR) | 0.71 | 0.45 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 18.29 | 9.80 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.